HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $33

Aktis Oncology, Inc. -4.47% Post

Aktis Oncology, Inc.

AKTS

16.88

16.88

-4.47%

0.00% Post
HC Wainwright & Co. analyst Robert Burns maintains Aktis Oncology (NASDAQ: AKTS) with a Buy and raises the price target from $30 to $33.